Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease — EAS Consensus Statement

For decades the relationship between LDL cholesterol and heart disease was described, cautiously, as an association. This consensus statement is the document that retired the caution. Its title is its thesis: low-density lipoproteins cause atherosclerotic cardiovascular disease.

The argument is the most complete of its kind. The European Atherosclerosis Society panel assembled the three independent lines of evidence that, taken together, satisfy the formal criteria for causation: genetic studies and Mendelian randomization (people born with lifelong low LDL are protected, in proportion to their exposure), epidemiology (the dose-response relationship across populations), and randomized trials of LDL-lowering drugs of every mechanism. Spanning over two million participants and 150,000 cardiovascular events, the synthesis shows a consistent, dose-dependent, log-linear relationship: it is the cumulative burden of LDL over a lifetime that drives the disease.

That last point is the practical payload, and it reframes the whole prevention enterprise. If risk accumulates with LDL exposure over time, then when you lower it matters as much as whether you do — earlier intervention buys more protection than the same intervention started late. The disease is built quietly, over decades, before it ever announces itself.

There is little to fault here on the merits; the honest note is simply that a consensus statement synthesizes existing evidence rather than generating new trials, and the “causation” framing, while rigorous, was the panel’s interpretive judgment on a body of data.

We rate the evidence very strong — among the most important documents in the modern understanding of cardiovascular disease. It is the intellectual foundation beneath “lower, earlier, for longer,” and beneath the case for finding and treating subclinical disease before it does its damage.